Analysis | Number of studies | References | Treatment group (episodes/total patients) | Control group (episodes/total patients) | OR (95% CI) | Pvalue | I 2 |
---|---|---|---|---|---|---|---|
SSI high-risk patients | 13 | [22], [24, 25], [27], [30–32], [34], [36–38], [44], [46] | 109/1,483 | 177/1,522 | 0.48 (0.33 to 0.70) | 0.0001 | 21% |
SSI studies providing definitions consistent with CDC criteria | 8 | 32/362 | 74/390 | 0.37 (0.23 to 0.58) | 0.0001 | 0% | |
Pneumonia high-risk patients | 12 | 115/1,444 | 155/1,428 | 0.70 (0.54 to 0.91) | 0.008 | 0% | |
Pneumonia studies providing definitions consistent with CDC criteria | 9 | 99/1,289 | 141/1,341 | 0.70 (0.53 to 0.93) | 0.01 | 0% | |
UTI high-risk patients | 10 | 13/458 | 31/449 | 0.44 (0.22 to 0.88) | 0.02 | 1% | |
UTI studies providing definitions consistent with CDC criteria | 7 | 9/298 | 24/326 | 0.45 (0.20 to 0.99) | 0.05 | 0% |